35 results about "Pharmacological interventions" patented technology

This invention defines a novel method for treatment of several neurological diseases and pathophysiologically related symptomology, said diseases including peripheral neuropathies, secondary symptomology of diabetes, Alzheimer's disease, Parkinson's disease, alcoholic polyneuropathy and age-onset symptomology, as well as analogous veterinary disease states. An opportunity exists for pharmacological intervention in some neurological diseases by use of water soluble, small molecular weight primary amine agents and chemical derivatives thereof. Examples of such primary pharmacological agents include 4-aminobenzoic acid and derivatives thereof. The present invention also includes: (1) oral use of optional non-absorbable polyamine polymeric co-agents such as chitosan, (2) oral use of optional known antioxidant co-agents and nutritional factors related thereto, and (3) use of the primary agents and co-agents noted above in optional combination with medicaments recognized as effective for treatment of the diseases addressed herein or symptoms thereof.

The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.

A system for certification of animals, owners, attendants, venues, enterprises, and events relies on identification, traceability, and evaluation against selected criteria. Data maintained during agricultural production includes production, raising, selling, holding, treating, harvesting products like milk or wool, slaughter, transfer of ownership or venue, and veterinary and pharmacological interventions, whether medicaments, preventives, protocols, treatments, or inspections administered. Record keeping and selection, analysis, and notifications are according to criteria (particularly risks, exposures, or both) specified by any entity requesting or requiring a certification of a condition or lack thereof. Warnings may be triggered and distributed timely. Mobile units avoid traditional deficiencies in data, analysis, risk assessment, and timeliness.

The invention discloses a feed for inducing high-level expression of a reactive protein C of an animal and application thereof. The feed for inducing high-level expression of the reactive protein C of the animal comprises the following components in percentage by mass: 10-20% of leaf lard, 1-2% of cholesterol and the balance of a basal feed in growing period, totaling 100%. Researches on high expression of CRP of machin diet-induced by the feed for inducing high-level expression of the reactive protein C of the animal have related important research significance and application value. The feed further has important actual meaning on research of inflammatory diseases and mechanism research of inflammatory diseases such as atherosclerosis, cardiovascular disease and even diabetes and arthritis, research on early warning and efficacy evaluation after pharmacological intervention. The raw materials of the feed for inducing high-level expression of the reactive protein C of the animal disclosed by the invention are low in cost, wide in source, easily available and good in stability, and the feed for inducing high-level expression of the reactive protein C of the animal is simple in preparation method, easy to convey and store and has relatively good application and popularization prospects.

The invention discloses a method for establishing an experimental model of a diabetic foot ulcer big mouse infected by staphylococcus aureus. The method includes the following steps that after the big mouse is fed on high-fat diet for eight weeks, streptozotocin is injected, and a diabetic model is manufactured. After the diabetic model is stabilized, II-degree scalding is performed on the skin of the big mouse, and after three days, subcutaneous injection of suspension liquid with staphylococcus aureus as the bacterial strain is performed in each ulcer position. In addition, the invention further discloses a kit for establishing the experimental model of the diabetic foot ulcer big mouse infected by the staphylococcus aureus, wherein the kit comprises the staphylococcus aureus suspension liquid. The diabetic foot ulcer experimental animal model detects variation of biochemical indexes after pharmacological intervention, and a result shows that the model has the infection features of diabetic foot ulcer and concurrent gram-positive bacteria. The model has the advantages of being short in ulcer wound surface healing time, sensitive to drug reaction and the like.

The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.

A pharmaceutical formulation capable of supplying replacement blood volume and tissue oxygenation as well as other functions, such as procoagulation and pharmacological interventions, in order to enhance survivability in patients with severe blood loss. The invention also discloses a formulation and method of using the formulation in bridging severe blood loss using a multifunctional blood substitute in a prehospital setting.

The invention relates to application of a fat emulsion injection using a vitamin K1. Particularly, the invention relates to an emulsion composition comprising the vitamin K1, soybean oil, phospholipid, glycerin and water. The emulsion composition is prepared by processes of preparation of a aqueous phase, preparation of an oil phase, preparation of a coarse emulsion, high-pressure emulsification,hot press sterilization and the like. The invention further relates to a method for preparing the emulsion composition and pharmaceutical application of the emulsion composition. The emulsion injection is used for insufficiency of the vitamin K or coagulation disorder diseases caused by dyssynthesis of coagulation factors II, VII, IX and X, which are generated due to pharmacological intervention interfering the activity of the vitamin K. The emulsion composition disclosed by the invention shows one or various technical effects as shown in the specification.

The invention discloses a method for establishing an experimental model of a diabetic foot ulcer big mouse infected by Escherichia coli. The method includes the following steps that after the big mouse is fed on high-fat diet for eight weeks, streptozotocin is injected, and a diabetic model is manufactured. After the diabetic model is stabilized, II-degree scalding is performed on the skin of the big mouse, and after three days, subcutaneous injection of Escherichia coli suspension liquid is performed in each ulcer position. In addition, the invention further discloses a kit for establishing the experimental model of the diabetic foot ulcer big mouse infected by the Escherichia coli, wherein the kit comprises the Escherichia coli suspension liquid. The diabetic foot ulcer experimental animal model detects variation of biochemical indexes after pharmacological intervention, and a result shows that the model has the infection features of diabetic ulcer and concurrent Gram-negative bacteria. The model has the advantages of being short in ulcer wound surface healing time, sensitive to drug reaction and the like.

The invention relates to a vitamin K1 fat emulsion injection. Particularly, the emulsion composition comprises a vitamin K1, soybean oil, phospholipid, glycerin and water. The composition is preparedby processes of preparation of a aqueous phase, preparation of an oil phase, preparation of a coarse emulsion, high-pressure emulsification, hot press sterilization and the like. The invention furtherrelates to a method for preparing the emulsion composition and pharmaceutical application of the emulsion composition. The emulsion injection is used for insufficiency of the vitamin K or coagulationdisorder diseases caused by dyssynthesis of coagulation factors II, VII, IX and X, which are generated due to pharmacological intervention interfering the activity of the vitamin K. The emulsion composition disclosed by the invention shows one or various technical effects as shown in the specification. For example, the composition can be used according to a dose of 10mg each time, 1 to 2 times per day and a total dose of 40mg at most in 24 hours, and an administration dosage and frequency are regulated according to prothrombin time response or clinical symptoms; the using mode is intravenousadministration, infusion can directly adopt intravenous injection without dilution, or the vitamin K1 fat emulsion injection is subjected to intravenous dripping after being diluted with 5% glucose injection.

This is the first ever report to uncover a tangible lipidomic basis by which maternal emotional well-being may influence fetal neuro-development and the later risk for psychopathology. This novel insight points to the potential utility of nutritional approaches among pregnant women with high levels of depressive symptoms in the prevention of offspring risk for later socio-emotional behavioral problems predictive of future psychopathology. Such a novel approach is particularly pertinent in light of the preference to avoid pharmacological interventions such as anti-depressant medications during pregnancy.

The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.